GlassScriptPhysician profile
Leslie Brown
NPI 1700039070
$2,514.20
in general payments reported to CMS, 2019-2025
24 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $551 · 2023: $731 · 2024: $154 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.91 | 2021-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $363.12 | 2021-2022 | |
| Lilly USA, LLC | $286.09 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $226.62 | 2021-2023 | |
| Pfizer INC. | $219.49 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2023 | Camzyos |
| Biohaven Pharmaceuticals, INC. | $124.58 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.43 | 2022-2023 | |
| Amgen INC. | $65.46 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $59.97 | 2022 | |
| Glaxosmithkline, LLC. | $57.79 | 2022-2023 | Arexvy, Shingrix |
| Coloplast Corp | $55.59 | 2024 | |
| Amarin Pharma, INC. | $30.26 | 2021 | |
| Radius Health, INC. | $30.13 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.17 | 2022 | |
| Merck Sharp & Dohme LLC | $29.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.27 | 2022-2023 | Xifaxan |
| Inspire Medical Systems, INC. | $20.96 | 2023 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $20.51 | 2022 | |
| Insightec,INC | $19.78 | 2023 | Exablate |
| Exact Sciences Corporation | $14.73 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.